{"id":"W3130435961","doi":"10.1158/1538-7445.sabcs20-ps10-05","title":"Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Letrozole; Clinical endpoint; Internal medicine; Discontinuation; Breast cancer; Adverse effect; Population; Goserelin; Metastatic breast cancer; Phases of clinical research; Oncology; Cancer; Clinical trial; Gastroenterology; Surgery; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001069836,0.0006135734,0.0007302416,0.0002279839,0.0001743778,0.0006802191,0.0004274142,0.0004927835,0.00947878],"category_scores_gemma":[0.0009798398,0.0001581012,0.000782972,0.0002615968,0.0003597781,0.0004106692,0.0003072623,0.001769187,0.001004993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008829188,"about_ca_system_score_gemma":0.001308873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0011603,"about_ca_topic_score_gemma":0.005285101,"domain_scores_codex":[0.9997123,0.0001467847,0.00001494669,0.000047969,0.00003417626,0.00004378228],"domain_scores_gemma":[0.9995881,0.00009156119,0.0001121235,0.00004085824,0.00002889667,0.0001384516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7373638,0.01018933,0.009324124,0.001728677,0.002318546,0.0002232837,0.0001911602,0.003216817,0.03487399,0.000718195,0.02109401,0.1787581],"study_design_scores_gemma":[0.6386623,0.2918925,0.03689337,0.0001544703,0.001866065,0.0005425605,0.00008515581,0.002116987,0.007585763,0.00057961,0.01957391,0.00004738025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696383,0.006523553,0.0007189104,0.001264648,0.0001562248,0.002186272,0.006253577,0.0003151552,0.01294325],"genre_scores_gemma":[0.9815614,0.001795696,0.001172152,0.001175979,0.0001629891,0.0009415867,0.007564586,0.00003498029,0.005590645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00947878,"threshold_uncertainty_score":0.03170967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04300735938034665,"score_gpt":0.3947596595600426,"score_spread":0.3517523001796959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}